Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure. (6th May 2022)

• Record Type: Journal Article
• Authors: Mukherjee, Dwaipayan; Chiney, Manoj S.; Shao, Xi; Ju, Tzuchi R.; Shebley, Mohamad; Marroum, Patrick
• Is Part Of: Biopharmaceutics & drug disposition. Volume 43:Number 3(2022)
• Page Start: 98
• Page End: 107
• Publication Date: 2022-05-06
• Subjects: biopharmaceutics -- dissolution specifications -- PBPK modeling; Biopharmaceutics -- Periodicals; Drugs -- Metabolism -- Periodicals; Pharmacology -- Periodicals; Biopharmaceutics -- Periodicals; Pharmaceutical Preparations -- metabolism -- Periodicals; 615.19
• DOI: 10.1002/bdd.2315
• Languages: English
• ISSNs: 0142-2782

Abstract

Abstract: The aim of this analysis was to use a physiologically based pharmacokinetic (PBPK) model to predict the impact of changes in dissolution rates on elagolix exposures and define clinically relevant acceptance criteria for dissolution. Varying in vitro dissolution profiles were utilized in a PBPK model to describe the absorption profiles of elagolix formulations used in Phase 3 clinical trials and for the to be marketed commercial formulations. Single dose studies of 200 mg elagolix formulations were used for model verification under fasted conditions. Additional dissolution scenarios were evaluated to assess the impact of dissolution rates on elagolix exposures. Compared to the Phase 3 clinical trial formulation, sensitivity analysis on dissolution rates suggested that a hypothetical scenario of ∼75% slower dissolution rate would result in 14% lower predicted elagolix plasma exposures, however, the predicted exposures are still within the bioequivalence boundaries of 0.8–1.25 for both Cmax and AUC. A clinically verified PBPK model of elagolix was utilized to evaluate the impact of wider dissolution specifications on elagolix plasma exposures. The simulation results indicated that a slower in vitro dissolution profile, would not have a clinically significant impact on elagolix exposures. These model results informed the setting of wider dissolution specifications without requiring in vivo studies. Abstract : This analysis used a physiologically based pharmacokinetic model to predict the impact of changes in dissolution rates on elagolix exposures and define clinically relevant acceptance criteria for dissolution. The simulation results indicated that a slower in vitro dissolution profile would not have clinically significant impact on elagolix exposures and informed setting of wider dissolution specifications without requiring in vivo studies.